Related Experiment Video
Updated: Jan 7, 2026
12:09
Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
Published on: February 28, 2019
10.2K
MGAT1 knockout in human dendritic cells enhance CD8+ T cell activation
Anne Louise Blomberg1, Betina Lyngfeldt Henriksen2, Weihua Tian1
1Biotherapeutic Glycoengineering and Immunology, Section for Medical Biotechnology, Department of Biotechnology and Biomedicine, Technical University of Denmark, Kgs Lyngby, Denmark.
Frontiers in Immunology
|January 2, 2026
Summary
Genetically engineering dendritic cells (DCs) by knocking out MGAT1 enhances their immunostimulatory capacity. This glycoengineering approach improves DC function for potential immunotherapy applications.
Area of Science:
- Immunology
- Glycobiology
- Cancer Immunotherapy
Background:
- Dendritic cells (DCs) are key regulators of immune responses and targets for immunotherapy.
- Current DC vaccines show promise but require enhanced functionality for greater clinical efficacy.
- While sialoglycans' roles in DCs are emerging, other glycans' structure-function relationships are less understood.
Purpose of the Study:
- To investigate the impact of N-glycan structure on DC biology and function by knocking out mannosyl (α-1,3-)-glycoprotein β-1,2-N-acetylglucosaminyltransferase (MGAT1).
- To understand how shifting from complex to oligomannose N-glycans affects DC differentiation and immunostimulatory potential.
Main Methods:
- Utilized a human MUTZ-3-derived DC model system, genetically engineered to lack MGAT1 (MGAT1 KO).
- Differentiated MGAT1 KO MUTZ-3 cells into immature DCs (iDCs) and compared their phenotype and function to wild-type (WT) iDCs.
- Analyzed DC marker expression, T cell activation, cytokine secretion, and NF-κB pathway activity.
Main Results:
- MGAT1 KO DCs exhibited normal differentiation marker expression but increased surface levels of CD40, HLA-ABC, and HLA-DR.
- MGAT1 KO iDCs showed elevated mRNA levels of NFKB1 and IFNB1, indicating enhanced immunostimulatory potential.
- MGAT1 KO iDCs significantly enhanced CD8+ T cell activation, proliferation, and pro-inflammatory cytokine secretion, even under PD-L1 blockade.
Conclusions:
- The absence of complex and hybrid N-glycans, due to MGAT1 KO, promotes accelerated DC differentiation and enhances DC immunostimulatory function.
- Enhanced NF-κB activity in MGAT1 KO DCs drives increased HLA and costimulatory molecule expression, leading to robust T cell activation.
- Glycoengineering DCs by modulating N-glycan structures offers a promising strategy to improve DC-based immunotherapies.
